Form 4: Intellia Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Jing L. Marantz, EVP, Chief Medical Officer of Intellia Therapeutics, Inc., reported multiple transactions in common stock on October 26, 2026.
Summary
- Grant/award: acquired 199,822 Common Stock on October 26, 2026; holds 199,822 after (Direct).
- Grant/award: acquired 275,061 Stock Option (right to buy) on October 26, 2026; holds 275,061 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jing L. Marantz — Officer (EVP, Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-26 | Grant/award | Common Stock | 199,822 | — | — | 199,822 |
| 2026-10-26 | Grant/award | Stock Option (right to buy) | 275,061 | — | — | 275,061 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-26 | Grant/award (199,822 shares) |
| 2026-10-26 | Grant/award (275,061 shares) |
Keywords
insider transaction, Form 4, NTLA, Intellia Therapeutics, Inc., neutral, Jing L. Marantz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.